

Cite as: C. E. Nelson *et al.*, *Science*
10.1126/science.aad5143 (2015).

In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy

Christopher E. Nelson,^{1,2} Chady H. Hakim,³ David G. Ousterout,^{1,2} Pratiksha I. Thakore,^{1,2} Eirik A. Moreb,^{1,2} Ruth M. Castellanos Rivera,⁴ Sarina Madhavan,^{1,2} Xiufang Pan,³ F. Ann Ran,^{5,6} Winston X. Yan,^{5,7,8} Aravind Asokan,⁴ Feng Zhang,^{5,9,10,11} Dongsheng Duan,^{3,12} Charles A. Gersbach^{1,2,13*}

¹Department of Biomedical Engineering, Duke University, Durham, NC, USA. ²Center for Genomic and Computational Biology, Duke University, Durham, NC, USA. ³Department of Molecular Microbiology and Immunology, University of Missouri, Columbia, MO, USA. ⁴Gene Therapy Center, Departments of Genetics, Biochemistry and Biophysics, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. ⁵Broad Institute of MIT and Harvard, Cambridge, MA, USA. ⁶Society of Fellows, Harvard University, Cambridge, MA, USA. ⁷Graduate Program in Biophysics, Harvard Medical School, Boston, MA, USA. ⁸Harvard-MIT Division of Health Sciences and Technology, Harvard Medical School, Boston, MA, USA. ⁹McGovern Institute for Brain Research, Massachusetts Institute of Technology, Cambridge, MA, USA. ¹⁰Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, MA, USA. ¹¹Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA. ¹²Department of Neurology, University of Missouri, Columbia, MO, USA. ¹³Department of Orthopaedic Surgery, Duke University Medical Center, Durham, NC, USA.

*Corresponding author. E-mail: charles.gersbach@duke.edu

Duchenne muscular dystrophy (DMD) is a devastating disease affecting about 1 out of 5000 male births and caused by mutations in the dystrophin gene. Genome editing has the potential to restore expression of a modified dystrophin gene from the native locus to modulate disease progression. In this study, adeno-associated virus was used to deliver the CRISPR/Cas9 system to the *mdx* mouse model of DMD to remove the mutated exon 23 from the dystrophin gene. This includes local and systemic delivery to adult mice and systemic delivery to neonatal mice. Exon 23 deletion by CRISPR/Cas9 resulted in expression of the modified dystrophin gene, partial recovery of functional dystrophin protein in skeletal myofibers and cardiac muscle, improvement of muscle biochemistry, and significant enhancement of muscle force. This work establishes CRISPR/Cas9-based genome editing as a potential therapy to treat DMD.

Duchenne muscular dystrophy (DMD) is among the most prevalent fatal genetic diseases, occurring in 1 out of 5000 male births (1). It results in muscle degeneration, loss of mobility, and premature fatality. DMD mutations are often deletions of one or more exons in the dystrophin gene that disrupt the reading frame of the gene and lead to a complete loss of functional dystrophin expression. In contrast, Becker muscular dystrophy (BMD) is associated with much milder symptoms relative to DMD and is caused by internal, in-frame deletions of the dystrophin gene resulting in expression of a truncated but partially functional dystrophin protein (2). Because of the genetic nature of the disease, gene therapy is a promising option to treat DMD. However, the very large size of the dystrophin cDNA presents a challenge to gene delivery. Consequently, some therapeutic strategies aim to generate a BMD-like dystrophin. These approaches include the development of mini/micro-dystrophin genes for delivery by adeno-associated virus (AAV) vectors (3–6) and oligonucleotide-mediated exon skipping therapies designed to restore the reading frame of the transcript (7, 8). For example, removal of exon 51 can address 13% of DMD patient mutations, and exon skipping strategies could be extended to other regions of the gene to collectively treat 83% of DMD patients (9). In contrast, genome editing technologies can be used to directly correct

disease-causing genetic mutations (10) and may be a preferred approach for a single treatment to restore stable expression of a dystrophin protein that contains most of the normal structure and function and is also under physiologic control of the natural promoter. In particular, the CRISPR/Cas9 genome editing system, which uses the Cas9 nuclease to cleave DNA sequences targeted by a single guide RNA (gRNA) (11), has recently created new possibilities for gene therapy by making precise genome modifications possible in cultured cells (12–15) and in animal studies (16–19). Analogous to exon-skipping therapies, CRISPR-mediated removal of one or more exons from the genomic DNA could be applied to the treatment of 83% of DMD patients. Moreover, this approach can be easily extended to targeting multiple exons within mutational hotspots, such as the deletion of exons 45–55 that could address 62% of DMD patients with a single gene editing strategy (20). We and others have applied these tools to correct dystrophin mutations in cultured human cells from DMD patients (20–25) and in *mdx* mouse embryos (26). A critical remaining challenge is to translate these proof-of-principle results into a clinically relevant approach for genome editing in muscle tissue in vivo. The use of genome editing for exon removal, rather than replacing missing exons to restore a full-length gene, may be desirable for several reasons. Editing by exon removal takes ad-

vantage of the relatively efficient non-homologous end joining pathway that is active in all cell types, in contrast to targeted gene addition by the homology-directed repair pathway that is downregulated in post-mitotic cells such as skeletal myocytes and myofibers. This method also avoids the need to deliver a DNA repair template. Finally, gene editing to delete exons will be more applicable to large patient populations that include a variety of mutations, in contrast to patient-specific editing strategies that restore unique gene deletions.

The *mdx* mouse model of DMD has a nonsense mutation in exon 23, which prematurely terminates protein production (27). Removal of exon 23 from the transcript through oligonucleotide-mediated exon skipping restores functional dystrophin expression and improves muscle contractility (28, 29). Here, we have developed an AAV-based strategy for the treatment of DMD in the *mdx* mouse by harnessing the unique multiplexing capacity of CRISPR/Cas9 to excise exon 23 from the dystrophin gene. We hypothesized that CRISPR-mediated removal of exon 23 from the genomic DNA would restore dystrophin expression and improve muscle function (Fig. 1a).

We used AAV serotype 8 (AAV8) as a vector for delivery and expression of the components of the CRISPR/Cas9 system to skeletal and cardiac muscle (30). Due to the packaging size restrictions of AAV (~4.7 kb), we utilized the 3.2 kb *Staphylococcus aureus* Cas9 (SaCas9) cDNA that was recently described for in vivo genome editing applications (19). A second AAV vector with two guide RNA (gRNA) expression cassettes was also produced to express gRNAs targeted to introns 22 and 23. We expected that simultaneous DNA cleavage in both introns by Cas9/gRNA complexes would remove exon 23 from the genome and result in production of an internally truncated, but highly functional, dystrophin protein. A panel of gRNAs was designed by manual inspection for the SaCas9 PAM (5'-NNGRRT-3') with close proximity to exon 23 and prioritized according to predicted specificity by minimizing potential off-target sites in the mouse genome. The best set of gRNAs was then selected based on in vitro gene editing efficiency (fig. S1).

The Cas9 and gRNA AAV vectors were premixed in equal amounts and injected into the tibialis anterior muscle of *mdx* mice. Contralateral limbs received saline injection. At eight weeks post-injection, the muscles were harvested and analyzed for deletion of exon 23 from the genomic DNA and mRNA, and expression of dystrophin protein. End-point PCR across the genomic locus revealed the expected ~1,171 bp deletion in all injected limbs (Fig. 1b). Droplet digital PCR (ddPCR) was used to quantify the percent of modified alleles by separately amplifying the unmodified or deleted DNA templates. ddPCR showed that exon 23 was deleted in ~2% of all alleles from the whole muscle lysate (Fig. 1c).

Sanger sequencing of gel-extracted bands confirmed the deletion of exon 23 as predicted without any additional indels (Fig. 1b). Deep sequencing of these amplicons indicated a strong preference (~66%) for precise ligation of cut products (fig. S2). Regardless, the distribution of indels in the deletion should not impact transcript production as the indels occur in the intronic region. Deep sequencing of gRNA target sites and the top 10 predicted off-target sites for each gRNA indicated ~3% indel formation at the target sites and low (~1%, gRNA1-OT8) or undetectable off-target gene editing at the predicted off-target sites (tables S2-S3, fig. S3).

RT-PCR of mRNA extracted from muscle lysates showed a fraction of transcripts without exon 23 (Fig. 1d). Quantitative ddPCR of the cDNA also showed significant editing of the mRNA transcript with exon 23 excluded in 59% of transcripts (Fig. 1e). The high frequency of mRNA modification is likely due to protection of the Δ 23 transcripts from nonsense-mediated decay. This is supported by an increase in total dystrophin mRNA from 5% of wild-type mRNA levels in non-treated muscles to 12% in Cas9/gRNA-treated muscles (fig. S4).

Western blot of whole muscle lysates showed substantial recovery of dystrophin protein to ~8% of the normal level (Fig. 2a). By immunostaining, ~67% of myofibers expressed dystrophin (Fig. 2b, Fig. 3a). Immunofluorescence staining also confirmed Cas9 expression in myonuclei (fig. S5). Collectively, the molecular analyses of genomic deletion, exon removal from the transcript, and abundant protein expression validated CRISPR-mediated restoration of a near-full length dystrophin protein to levels above the established benchmarks for functional recovery and therapeutic benefit. In particular, it is reported that as little as 4% of normal dystrophin expression level is sufficient to improve muscle function (31, 32), and human natural history studies show that 30% protein expression may be sufficient for a completely asymptomatic phenotype (33). Therefore we evaluated therapeutic benefit in CRISPR-treated *mdx* mice. We first examined sarcolemmal neuronal nitric oxide synthase (nNOS) localization. nNOS is absent in the sarcolemma of the *mdx* mouse and DMD patients due to the loss of the nNOS-binding site in spectrin repeats 16 and 17 in the dystrophin protein (34, 35). The mislocalization of nNOS contributes to DMD pathogenesis (34, 35). In CRISPR-treated muscles, nNOS activity was restored at the sarcolemma closely mirroring dystrophin staining in serial sections (Fig. 3a-b) and resembling that of wild-type muscle (fig. S6).

Dystrophin assembles a series of transmembrane and cytosolic proteins into the dystrophin-associated glycoprotein complex (DGC) to link the cytoskeleton and the extracellular matrix (1). In *mdx* mice and DMD patients, these proteins are mislocalized. Immunostaining of serial muscle sections showed recovery of DGC proteins in Cas9/gRNA-treated

muscles, but not the contralateral controls (figs. S7-S9). Histological examination showed improved overall morphology of CRISPR/Cas9-treated muscles, including reduced fibrosis (Fig. 3c, fig. S10). The number of infiltrating macrophages and neutrophils was substantially decreased in treated muscle, indicating a reduction of the inflammation typical of dystrophic muscle (fig. S11). Hematoxylin and eosin staining of serial sections showed no obvious response to the vector or transgene in this study (Fig. 3c). However, potential immune responses to the AAV capsid, Cas9, and dystrophin are important subjects for future studies (6, 36–38).

Next, we assessed muscle function. The specific twitch (Pt) and tetanic (Po) force were significantly improved in Cas9/gRNA-treated muscle (* $p < 0.05$, Fig. 3d). Treated muscles showed significantly improved resistance to eccentric contraction injury, maintaining 50% of the initial force relative to 37% in untreated muscle (* $p < 0.05$ at marked cycles, Fig. 3d). Further, pathologic hypertrophy was mitigated in Cas9/gRNA-treated muscle (table S4). Collectively these results show that CRISPR/Cas9-mediated dystrophin restoration improved muscle structure and function.

To assess the effects of dystrophin restoration early in life, we performed intraperitoneal injections of the AAV vector into P2 neonatal mice. This led to recovered dystrophin expression in abdominal muscles, diaphragm, and heart at seven weeks post-injection (figs. S12-S13). Importantly, these muscles are responsible for cardiac and pulmonary health, which are severely weakened and responsible for the premature death of DMD patients. Finally, intravenous administration of AAV vectors in six-week-old adult *mdx* showed significant recovery of dystrophin in the cardiac muscle (Fig. 4). Efficient cardiac correction will be a significant end-point to prevent premature death of DMD patients.

In this study we have demonstrated the therapeutic benefit of AAV-mediated CRISPR/Cas9 genome editing in an adult mouse model of DMD. Our results include correction in a single muscle following local delivery and in the heart following intravenous delivery to neonatal and adult mice. As systemic delivery of AAV vectors to skeletal and cardiac tissue is well-established, we expect this approach to confer body-wide therapeutic benefits. The accompanying article from Wagers and colleagues (39) uses a similar approach to CRISPR/Cas9-based correction of dystrophic mice using delivery with AAV9, demonstrating generality across muscle-tropic AAV serotypes. Moreover, their demonstration of efficient editing of Pax7-positive muscle satellite cells (39) suggests that gene correction may improve as the mature muscle fibers are populated with the progeny of these progenitor cells, as was observed in mosaic mice generated by CRISPR/Cas9 delivery to single cell zygotes (26). In fact, we have observed that dystrophin restoration by genome editing is maintained for at least six months post-treatment (fig.

S14).

Continued optimization of vector design will be important for potential clinical translation of this approach, including evaluation of various AAV capsids and tissue-specific promoters. Additionally, although dual vector administration has been effective in body-wide correction of animal models of DMD (40), optimization to engineer a single vector approach may increase efficacy and translatability. These two studies (39) establish a strategy for gene correction by a single gene editing treatment that has the potential to achieve similar effects as seen with weekly administration of exon skipping therapies (7, 8, 28, 29). More broadly, this work establishes CRISPR/Cas9-mediated genome editing as an effective tool for gene modification in skeletal and cardiac muscle and as a therapeutic approach to correct protein deficiencies in neuromuscular disorders and potentially many other diseases. The continued development of this technology to characterize and enhance the safety and efficacy of gene editing will help to realize its promise for treating genetic disease

REFERENCES AND NOTES

1. R. J. Fairclough, M. J. Wood, K. E. Davies, Therapy for Duchenne muscular dystrophy: Renewed optimism from genetic approaches. *Nat. Rev. Genet.* **14**, 373–378 (2013). [Medline doi:10.1038/nrg3460](#)
2. S. B. England, L. V. Nicholson, M. A. Johnson, S. M. Forrest, D. R. Love, E. E. Zubrzycka-Gaarn, D. E. Bulman, J. B. Harris, K. E. Davies, Very mild muscular dystrophy associated with the deletion of 46% of dystrophin. *Nature* **343**, 180–182 (1990). [Medline doi:10.1038/343180a0](#)
3. B. Wang, J. Li, X. Xiao, Adeno-associated virus vector carrying human minidystrophin genes effectively ameliorates muscular dystrophy in mdx mouse model. *Proc. Natl. Acad. Sci. U.S.A.* **97**, 13714–13719 (2000). [Medline doi:10.1073/pnas.240335297](#)
4. S. Q. Harper, M. A. Hauser, C. DelloRusso, D. Duan, R. W. Crawford, S. F. Phelps, H. A. Harper, A. S. Robinson, J. F. Engelhardt, S. V. Brooks, J. S. Chamberlain, Modular flexibility of dystrophin: Implications for gene therapy of Duchenne muscular dystrophy. *Nat. Med.* **8**, 253–261 (2002). [Medline doi:10.1038/nm0302-253](#)
5. J. H. Shin, X. Pan, C. H. Hakim, H. T. Yang, Y. Yue, K. Zhang, R. L. Terjung, D. Duan, Microdystrophin ameliorates muscular dystrophy in the canine model of duchenne muscular dystrophy. *Mol. Ther.* **21**, 750–757 (2013). [Medline doi:10.1038/mt.2012.283](#)
6. J. R. Mendell, K. Campbell, L. Rodino-Klapac, Z. Sahenk, C. Shilling, S. Lewis, D. Bowles, S. Gray, C. Li, G. Galloway, V. Malik, B. Coley, K. R. Clark, J. Li, X. Xiao, J. Samulski, S. W. McPhee, R. J. Samulski, C. M. Walker, Dystrophin immunity in Duchenne's muscular dystrophy. *N. Engl. J. Med.* **363**, 1429–1437 (2010). [Medline doi:10.1056/NEJMoa1000228](#)
7. S. Cirak, V. Arechavala-Gomez, M. Guglieri, L. Feng, S. Torelli, K. Anthony, S. Abbs, M. E. Garralda, J. Bourke, D. J. Wells, G. Dickson, M. J. Wood, S. D. Wilton, V. Straub, R. Kole, S. B. Shrewsbury, C. Sewry, J. E. Morgan, K. Bushby, F. Muntoni, Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: An open-label, phase 2, dose-escalation study. *Lancet* **378**, 595–605 (2011). [Medline doi:10.1016/S0140-6736\(11\)60756-3](#)
8. N. M. Goemans, M. Tulinius, J. T. van den Akker, B. E. Burm, P. F. Ekhardt, N. Heuvelmans, T. Holling, A. A. Janson, G. J. Platenburg, J. A. Sipkens, J. M. Sitsen, A. Aartsma-Rus, G. J. van Ommen, G. Buyse, N. Darin, J. J. Verschuuren, G. V. Campion, S. J. de Kimpe, J. C. van Deutekom, Systemic administration of PRO051 in Duchenne's muscular dystrophy. *N. Engl. J. Med.* **364**, 1513–1522 (2011). [Medline doi:10.1056/NEJMoa1011367](#)
9. A. Aartsma-Rus, I. Fokkema, J. Verschuuren, I. Ginjaar, J. van Deutekom, G. J. van

- Ommen, J. T. den Dunnen, Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations. *Hum. Mutat.* **30**, 293–299 (2009). [Medline doi:10.1002/humu.20918](#)
10. D. B. Cox, R. J. Platt, F. Zhang, Therapeutic genome editing: Prospects and challenges. *Nat. Med.* **21**, 121–131 (2015). [Medline doi:10.1038/nm.3793](#)
 11. M. Jinek, K. Chylinski, I. Fonfara, M. Hauer, J. A. Doudna, E. Charpentier, A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. *Science* **337**, 816–821 (2012). [Medline doi:10.1126/science.1225829](#)
 12. P. Mali, L. Yang, K. M. Esvelt, J. Aach, M. Guell, J. E. DiCarlo, J. E. Norville, G. M. Church, RNA-guided human genome engineering via Cas9. *Science* **339**, 823–826 (2013). [Medline doi:10.1126/science.1232033](#)
 13. L. Cong, F. A. Ran, D. Cox, S. Lin, R. Barretto, N. Habib, P. D. Hsu, X. Wu, W. Jiang, L. A. Marraffini, F. Zhang, Multiplex genome engineering using CRISPR/Cas systems. *Science* **339**, 819–823 (2013). [Medline doi:10.1126/science.1231143](#)
 14. S. W. Cho, S. Kim, J. M. Kim, J. S. Kim, Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease. *Nat. Biotechnol.* **31**, 230–232 (2013). [Medline doi:10.1038/nbt.2507](#)
 15. M. Jinek, A. East, A. Cheng, S. Lin, E. Ma, J. Doudna, RNA-programmed genome editing in human cells. *eLife* **2**, e00471 (2013). [Medline doi:10.7554/eLife.00471](#)
 16. H. Yin, W. Xue, S. Chen, R. L. Bogorad, E. Benedetti, M. Grompe, V. Kotliansky, P. A. Sharp, T. Jacks, D. G. Anderson, Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype. *Nat. Biotechnol.* **32**, 551–553 (2014). [Medline doi:10.1038/nbt.2884](#)
 17. L. Swiech, M. Heidenreich, A. Banerjee, N. Habib, Y. Li, J. Trombetta, M. Sur, F. Zhang, In vivo interrogation of gene function in the mammalian brain using CRISPR-Cas9. *Nat. Biotechnol.* **33**, 102–106 (2015). [Medline doi:10.1038/nbt.3055](#)
 18. R. J. Platt, S. Chen, Y. Zhou, M. J. Yin, L. Swiech, H. R. Kempton, J. E. Dahlman, O. Parnas, T. M. Eisenhaure, M. Jovanovic, D. B. Graham, S. Jhunjhunwala, M. Heidenreich, R. J. Xavier, R. Langer, D. G. Anderson, N. Hacohen, A. Regev, G. Feng, P. A. Sharp, F. Zhang, CRISPR-Cas9 knockin mice for genome editing and cancer modeling. *Cell* **159**, 440–455 (2014). [Medline doi:10.1016/j.cell.2014.09.014](#)
 19. F. A. Ran, L. Cong, W. X. Yan, D. A. Scott, J. S. Gootenberg, A. J. Kriz, B. Zetsche, O. Shalem, X. Wu, K. S. Makarova, E. V. Koonin, P. A. Sharp, F. Zhang, In vivo genome editing using *Staphylococcus aureus* Cas9. *Nature* **520**, 186–191 (2015). [Medline doi:10.1038/nature14299](#)
 20. D. G. Ousterout, A. M. Kabadi, P. I. Thakore, W. H. Majoros, T. E. Reddy, C. A. Gersbach, Multiplex CRISPR/Cas9-based genome editing for correction of dystrophin mutations that cause Duchenne muscular dystrophy. *Nat. Commun.* **6**, 6244 (2015). [Medline doi:10.1038/ncomms7244](#)
 21. D. G. Ousterout, P. Perez-Pinera, P. I. Thakore, A. M. Kabadi, M. T. Brown, X. Qin, O. Fedrigo, V. Mouly, J. P. Tremblay, C. A. Gersbach, Reading frame correction by targeted genome editing restores dystrophin expression in cells from Duchenne muscular dystrophy patients. *Mol. Ther.* **21**, 1718–1726 (2013). [Medline doi:10.1038/mt.2014.234](#)
 22. L. Popplewell, T. Koo, X. Leclerc, A. Duclert, K. Mamchaoui, A. Gouble, V. Mouly, T. Voit, F. Pâques, F. Cédronne, O. Isman, R. J. Yáñez-Muñoz, G. Dickson, Gene correction of a duchenne muscular dystrophy mutation by meganuclease-enhanced exon knock-in. *Hum. Gene Ther.* **24**, 692–701 (2013). [Medline doi:10.1089/hum.2013.081](#)
 23. D. G. Ousterout, A. M. Kabadi, P. I. Thakore, P. Perez-Pinera, M. T. Brown, W. H. Majoros, T. E. Reddy, C. A. Gersbach, Correction of dystrophin expression in cells from Duchenne muscular dystrophy patients through genomic excision of exon 51 by zinc finger nucleases. *Mol. Ther.* **23**, 523–532 (2015). [Medline doi:10.1038/mt.2014.234](#)
 24. H. L. Li, N. Fujimoto, N. Sasakawa, S. Shirai, T. Ohkame, T. Sakuma, M. Tanaka, N. Amano, A. Watanabe, H. Sakurai, T. Yamamoto, S. Yamanaka, A. Hotta, Precise correction of the dystrophin gene in duchenne muscular dystrophy patient induced pluripotent stem cells by TALEN and CRISPR-Cas9. *Stem Cell Rev.* **4**, 143–154 (2015). [doi:10.1016/j.stemcr.2014.10.013](#) [Medline doi:10.1038/nbt.2675](#)
 25. P. Chapdelaine, C. Pichavant, J. Rousseau, F. Pâques, J. P. Tremblay, Meganucleases can restore the reading frame of a mutated dystrophin. *Gene Ther.* **17**, 846–858 (2010). [Medline doi:10.1038/gt.2010.26](#)
 26. C. Long, J. R. McAnally, J. M. Shelton, A. A. Mireault, R. Bassel-Duby, E. N. Olson, Prevention of muscular dystrophy in mice by CRISPR/Cas9-mediated editing of germline DNA. *Science* **345**, 1184–1188 (2014). [Medline doi:10.1126/science.1254445](#)
 27. P. Sicsinski, Y. Geng, A. S. Ryder-Cook, E. A. Barnard, M. G. Darlison, P. J. Barnard, The molecular basis of muscular dystrophy in the mdx mouse: A point mutation. *Science* **244**, 1578–1580 (1989). [Medline doi:10.1126/science.2662404](#)
 28. C. J. Mann, K. Honeyman, A. J. Cheng, T. Ly, F. Lloyd, S. Fletcher, J. E. Morgan, T. A. Partridge, S. D. Wilton, Antisense-induced exon skipping and synthesis of dystrophin in the mdx mouse. *Proc. Natl. Acad. Sci. U.S.A.* **98**, 42–47 (2001). [Medline doi:10.1073/pnas.98.1.42](#)
 29. A. Goyenvalle, G. Griffith, A. Babbs, S. El Andaloussi, K. Ezzat, A. Avril, B. Dugovic, R. Chaussonot, A. Ferry, T. Voit, H. Amthor, C. Bühr, S. Schürch, M. J. Wood, K. E. Davies, C. Vaillend, C. Leumann, L. Garcia, Functional correction in mouse models of muscular dystrophy using exon-skipping tricyclo-DNA oligomers. *Nat. Med.* **21**, 270–275 (2015). [Medline doi:10.1038/nbt.1073](#)
 30. Z. Wang, T. Zhu, C. Qiao, L. Zhou, B. Wang, J. Zhang, C. Chen, J. Li, X. Xiao, Adeno-associated virus serotype 8 efficiently delivers genes to muscle and heart. *Nat. Biotechnol.* **23**, 321–328 (2005). [Medline doi:10.1038/nbt1073](#)
 31. D. Li, Y. Yue, D. Duan, Marginal level dystrophin expression improves clinical outcome in a strain of dystrophin/utrophin double knockout mice. *PLOS ONE* **5**, e15286 (2010). [Medline doi:10.1371/journal.pone.0015286](#)
 32. M. van Putten, M. Hulsker, C. Young, V. D. Nadarajah, H. Heemskerk, L. van der Weerd, P. A. 't Hoen, G. J. van Ommen, A. M. Aartsma-Rus, Low dystrophin levels increase survival and improve muscle pathology and function in dystrophin/utrophin double-knockout mice. *FASEB J.* **27**, 2484–2495 (2013). [Medline doi:10.1096/fj.12-224170](#)
 33. M. Neri, S. Torelli, S. Brown, I. Ugo, P. Sabatelli, L. Merlini, P. Spitali, P. Rimessi, F. Gualandi, C. Sewry, A. Ferlini, F. Muntoni, Dystrophin levels as low as 30% are sufficient to avoid muscular dystrophy in the human. *Neuromuscul. Disord.* **17**, 913–918 (2007). [Medline doi:10.1016/j.nmd.2007.07.005](#)
 34. Y. M. Kobayashi, E. P. Rader, R. W. Crawford, N. K. Iyengar, D. R. Thedens, J. A. Faulkner, S. V. Parikh, R. M. Weiss, J. S. Chamberlain, S. A. Moore, K. P. Campbell, Sarcolemma-localized nNOS is required to maintain activity after mild exercise. *Nature* **456**, 511–515 (2008). [Medline doi:10.1038/nature07005](#)
 35. Y. Lai, G. D. Thomas, Y. Yue, H. T. Yang, D. Li, C. Long, L. Judge, B. Bostick, J. S. Chamberlain, R. L. Terjung, D. Duan, Dystrophins carrying spectrin-like repeats 16 and 17 anchor nNOS to the sarcolemma and enhance exercise performance in a mouse model of muscular dystrophy. *J. Clin. Invest.* **119**, 624–635 (2009). [Medline doi:10.1172/JCI36612](#)
 36. S. Al-Zaidy, L. Rodino-Klapac, J. R. Mendell, Gene therapy for muscular dystrophy: Moving the field forward. *Pediatr. Neurol.* **51**, 607–618 (2014). [Medline doi:10.1016/j.pediatrneurol.2014.08.002](#)
 37. D. Wang, H. Mou, S. Li, Y. Li, S. Hough, K. Tran, J. Li, H. Yin, D. G. Anderson, E. J. Sontheimer, Z. Weng, G. Gao, W. Xue, Adenovirus-Mediated Somatic Genome Editing of Pten by CRISPR/Cas9 in Mouse Liver in Spite of Cas9-Specific Immune Responses. *Hum. Gene Ther.* **26**, 432–442 (2015). [Medline doi:10.1089/hum.2015.087](#)
 38. F. Mingozzi, K. A. High, Immune responses to AAV vectors: Overcoming barriers to successful gene therapy. *Blood* **122**, 23–36 (2013). [Medline doi:10.1182/blood-2013-01-306647](#)
 39. M. Tabeqbar *et al.*, *Science* (2015). [doi:10.1126/science.aad5177](#)
 40. Y. Lai, Y. Yue, M. Liu, A. Ghosh, J. F. Engelhardt, J. S. Chamberlain, D. Duan, Efficient in vivo gene expression by trans-splicing adeno-associated viral vectors. *Nat. Biotechnol.* **23**, 1435–1439 (2005). [Medline doi:10.1038/nbt1153](#)
 41. P. Mali, J. Aach, P. B. Stranges, K. M. Esvelt, M. Moosburner, S. Kosuri, L. Yang, G. M. Church, CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering. *Nat. Biotechnol.* **31**, 833–838 (2013). [Medline doi:10.1038/nbt.2675](#)
 42. D. Y. Guschin, A. J. Waite, G. E. Katibah, J. C. Miller, M. C. Holmes, E. J. Rebar, A rapid and general assay for monitoring endogenous gene modification. *Methods Mol. Biol.* **649**, 247–256 (2010). [Medline doi:10.1007/978-1-60761-753-2_15](#)
 43. S. Bae, J. Park, J. S. Kim, Cas-OFFinder: A fast and versatile algorithm that searches for potential off-target sites of Cas9 RNA-guided endonucleases. *Bioinformatics* **30**, 1473–1475 (2014). [Medline doi:10.1093/bioinformatics/btu048](#)

44. D. Li, A. Bareja, L. Judge, Y. Yue, Y. Lai, R. Fairclough, K. E. Davies, J. S. Chamberlain, D. Duan, Sarcolemmal nNOS anchoring reveals a qualitative difference between dystrophin and utrophin. *J. Cell Sci.* **123**, 2008–2013 (2010). [Medline doi:10.1242/jcs.064808](#)
45. C. H. Hakim, N. B. Wasala, D. Duan, Evaluation of muscle function of the extensor digitorum longus muscle ex vivo and tibialis anterior muscle in situ in mice. *J. Vis. Exp.* (72): (2013). [Medline](#)

ACKNOWLEDGMENTS

We thank M. Gemberling, T. Reddy, W. Majoros, F. Guilak, K. Zhang and Y. Yue for technical assistance and X. Xiao and E. Smith for helpful discussion. This work has been supported by the Muscular Dystrophy Association (MDA277360), a Duke-Coulter Translational Partnership Grant, a Hartwell Foundation Individual Biomedical Research Award, a March of Dimes Foundation Basil O'Connor Starter Scholar Award, and a National Institutes of Health (NIH) Director's New Innovator Award (DP2-OD008586) to C.A.G., as well as a Duke/UNC-Chapel Hill CTSA Consortium Collaborative Translational Research Award to C.A.G. and A.A. F.Z. is supported by an NIH Director's Pioneer Award (DPI-MH100706), NIH grant R01DK097768, a Waterman Award from the NSF, the Keck, Damon Runyon, Searle Scholars, Merkin Family, Vallee, Simons, Paul G. Allen, and the New York Stem Cell Foundations, and by Bob Metcalfe. A.A. is supported by NIH grants R01HL089221 and P01HL112761. D.D. is supported by NIH grant R01NS090634 and the Hope for Javier Foundation. C.E.N. is supported by a Hartwell Foundation Postdoctoral Fellowship. P.I.T. was supported by an American Heart Association Predoctoral Fellowship. W.X.Y. is supported by T32GM007753 from the National Institute of General Medical Sciences and a Paul and Daisy Soros Fellowship. F.A.R. is a Junior Fellow at the Harvard Society of Fellows. The SaCas9 gene is openly available through Addgene via a UBMTA. C.A.G., D.G.O., and P.I.T. are inventors on a patent application filed by Duke University related to genome editing for Duchenne muscular dystrophy (WO 2014/197748). F.Z. and F.A.R. are inventors on patents filed by the Broad Institute related to SaCas9 materials (US patents 8,865,406 and 8,906,616 and accepted EP 2898075, from International patent application WO 2014/093635). C.A.G. is a scientific advisor to Editas Medicine, a company engaged in development of therapeutic genome editing. F.Z. is a founder of Editas Medicine and scientific advisor for Editas Medicine and Horizon Discovery. D.D. is a member of the scientific advisory board for Solid GT, a subsidiary of Solid Biosciences.

SUPPLEMENTARY MATERIALS

www.sciencemag.org/cgi/content/full/science.aad5143/DC1

Materials and Methods

Figs. S1 to S22

Tables S1 to S4

References (41–45)

24 September 2015; accepted 7 December 2015

Published online 31 December 2015

10.1126/science.aad5143




Fig. 1. CRISPR/Cas9-mediated genomic and transcript deletion of exon 23 through intramuscular AAV-CRISPR administration. (a) The Cas9 nuclease is targeted to introns 22 and 23 by two gRNAs. Simultaneous generation of double stranded breaks (DSBs) by Cas9 leads to excision of the region surrounding the mutated exon 23. The distal ends are repaired through non-homologous end joining (NHEJ). The reading frame of the dystrophin gene is recovered and protein expression is restored. (b) PCR across the genomic deletion region shows the smaller deletion PCR product in treated muscles. Sequencing of the deletion band shows perfect ligation of Cas9 target sites (+, AAV-injected muscles; -, contralateral muscles). (c) ddPCR of deletion products shows 2% genome editing efficiency (n=6, mean+s.e.m.). (d) RT-PCR across exons 22 and 24 of dystrophin cDNA shows a smaller band that does not include exon 23 in treated muscles. Sanger sequencing confirmed exon 23 deletion. (e) ddPCR of intact dystrophin transcripts and $\Delta 23$ transcripts shows 59% of transcripts do not have exon 23 (n=6, mean+s.e.m.). bGHpA, bovine growth hormone polyadenylation sequence; ITR, inverted terminal repeat; NLS, nuclear localization signal. Asterisk, significantly different from the sham group ($p < 0.05$).




Fig. 2. In vivo genome editing restores dystrophin protein expression. (a) Western blot for dystrophin shows recovery of dystrophin expression (+, AAV-injected muscle; -, contralateral muscle). Comparison to protein from wild-type (WT) mice indicates restored dystrophin is ~8% of normal levels (n=6, mean+s.e.m.). (b) Dystrophin immunofluorescence staining shows abundant (67%) dystrophin-positive fibers in Cas9/gRNA treated groups (scale bar = 100 μ m, n=7, mean+s.e.m.). Asterisk, significantly different from the sham group (p<0.05)




Fig. 3. CRISPR/Cas9 gene editing restores nNOS activity and improves muscle function. (a) Whole muscle transverse sections show abundant dystrophin expression throughout the tibialis anterior muscle. (b) Staining of serial sections shows recruitment and activity of nNOS in a pattern similar to dystrophin expression. (c) H&E staining shows no obvious adverse response to the AAV/Cas9 treatment. Additionally, there is reduction of regions of necrotic fibers. Scale bars = 600 μ m in full-view images and 100 μ m in high-power images. (d) Significant improvement in specific twitch force (Pt) and tetanic force (Po) as measured by an in situ contractility assay in Cas9/gRNA-treated muscles. Treated muscles also showed significantly better resistance to damage caused by repeated cycles of eccentric contraction (n=7, mean+s.e.m). Overall treatment effect by ANOVA (p<0.05). Asterisk, significantly different from the sham group (p<0.05).




Fig. 4. Systemic delivery of CRISPR/Cas9 by intravenous injection restores dystrophin expression in adult *mdx* mouse cardiac muscle. (a) PCR across the deletion region in the genomic DNA from cardiac tissues shows the smaller deletion PCR product in all treated mice. (b) RT-PCR across exons 22 and 24 of dystrophin cDNA from cardiac tissue shows a smaller band that does not include exon 23 in treated mice. (c) Western blot for dystrophin in protein lysates from cardiac tissue shows recovery of dystrophin expression (+, AAV injected mice; -, saline injected controls). (d) Dystrophin immunofluorescence staining shows dystrophin recovery in cardiomyocytes. Scale bar = 100 μ m